FDA grants Fast Track designation to Teva's TEV-53408, an anti-IL-15 antibody for celiac disease in Phase 2a study. Teva Pharmaceutical Industries has received Fast Track designation from the FDA for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results